新冠“乙类乙管”政策下临床生物样本保藏及生物安全防护专家共识

Expert Consensus on Clinical Specimen Preservation and Biosafety Protection in the Context of Managing COVID-19 with Measures against Class B Infectious Diseases

  • 摘要: 随着新型冠状病毒感染(coronavirus disease 2019,COVID-19)的流行,国家对其防控政策历经“乙类甲管”至“乙类乙管”。在此背景下,生物样本库开展样本保藏活动时,需重新审视其带来的生物安全风险,并开展相应的生物安全防护实践,制订有效的管理措施。针对新型冠状病毒不断变异的特性和潜在风险,完善生物安全防护体系势在必行。中国研究型医院学会临床数据与样本资源库专业委员会和广东省人类遗传资源保藏应用学会共同起草并制定本共识,旨在为临床生物样本保藏活动提供安全防护实践指引,降低生物安全风险,确保临床生物样本保藏活动的安全顺利开展。

     

    Abstract: During the past three years, the national prevention and control policies for coronavirus disease 2019(COVID-19) have gone from"Class A control" to "Class B control". Therefore, it is necessary to reexamine the biosafety risks, carry out corresponding biosafety protection practices, and formulate management measures for clinical Biobank when conducting sample preservation activities. It is imperative to improve the biosafety protection system in view of the constantly mutating characteristics and potential risks of novel coronavirus. Professional Committee of Clinical Data and Sample Resource Database of China Research Hospital Association and the Human Genetic Resource Conservation and Application Society of Guangdong Province jointly drafted and formulated this consensus. We aim to provide practical guidance on biosafety protection for sample preservation activities, reduce biosafety risks, and ensure the safe and efficient implementation of sample preservation activities.

     

/

返回文章
返回